Table 1.

Baseline characteristics and disease status (safety population)

VariableCohorts 1–5, 0.5–15 mg/kg QW (n = 37)Cohorts 6–7, 30–45 mg/kg Q3W (n = 6)Total (N = 43)
Age (y), mean (SD)62.6 (11.5)62.0 (12.7)62.6 (11.6)
Sex, n, male/female23/142/425/18
Primary tumor type, n
 Bladder2020
 Breast (adenocarcinoma)11
 Cervical11
 Colorectal112
 Colon11
 Esophageal11
 Ewing's sarcoma11
 Gastroesophageal11
 Non–small cell lung11
 Ovarian11
 Prostate33
 Othera9110
Baseline Karnofsky performance status
 70639
 8013316
 901313
 10055

Abbreviations: QW, once weekly; Q3W, every 3 weeks.

  • aIncludes anal cancer, adrenal cortical carcinoma, leiomyosarcoma, uterine cancer, pancreatic carcinoma, angiosarcoma, liposarcoma, appendiceal adenocarcinoma, and adenocarcinoma of unknown primary origin.